NIKOLIC, Dragana
 Distribuzione geografica
Continente #
AS - Asia 1.183
NA - Nord America 1.094
EU - Europa 571
SA - Sud America 300
AF - Africa 35
OC - Oceania 3
AN - Antartide 1
Totale 3.187
Nazione #
US - Stati Uniti d'America 1.035
SG - Singapore 458
IT - Italia 245
HK - Hong Kong 243
BR - Brasile 226
CN - Cina 172
DE - Germania 104
VN - Vietnam 99
RU - Federazione Russa 58
FR - Francia 43
IN - India 37
GB - Regno Unito 29
ID - Indonesia 29
CA - Canada 28
AR - Argentina 25
BD - Bangladesh 24
IQ - Iraq 19
MX - Messico 19
FI - Finlandia 17
NL - Olanda 16
ZA - Sudafrica 13
VE - Venezuela 12
ES - Italia 11
SA - Arabia Saudita 11
TR - Turchia 11
EC - Ecuador 10
JP - Giappone 10
CO - Colombia 9
PH - Filippine 9
UZ - Uzbekistan 9
AT - Austria 7
NP - Nepal 7
HN - Honduras 6
PY - Paraguay 6
RS - Serbia 6
SE - Svezia 6
BE - Belgio 5
EG - Egitto 5
IL - Israele 5
PK - Pakistan 5
PL - Polonia 5
CL - Cile 4
JO - Giordania 4
KG - Kirghizistan 4
LT - Lituania 4
MA - Marocco 4
MY - Malesia 4
UA - Ucraina 4
UY - Uruguay 4
AU - Australia 3
TH - Thailandia 3
TN - Tunisia 3
BH - Bahrain 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GR - Grecia 2
IR - Iran 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
QA - Qatar 2
TJ - Tagikistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MM - Myanmar 1
MN - Mongolia 1
NA - Namibia 1
NG - Nigeria 1
PE - Perù 1
RO - Romania 1
SN - Senegal 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 3.187
Città #
Hong Kong 242
Singapore 148
San Jose 145
Ashburn 137
Beijing 95
Milan 64
Ho Chi Minh City 32
Los Angeles 31
Dallas 30
Bari 28
New York 28
Rome 28
Wermelskirchen 28
Columbus 24
Council Bluffs 23
Falkenstein 22
Chicago 20
Hanoi 19
Lauterbourg 19
Santa Clara 19
Boardman 18
Buffalo 18
São Paulo 18
Düsseldorf 17
Jakarta 15
Munich 15
Helsinki 13
Orem 13
Frankfurt am Main 11
Brooklyn 9
Denver 9
San Francisco 9
Tashkent 9
Vancouver 9
Chennai 8
London 8
Mexico City 8
Rio de Janeiro 8
Tokyo 8
Baghdad 7
Nuremberg 7
Tenafly 7
Amsterdam 6
Belgrade 6
Toronto 6
Caracas 5
Catania 5
Charlotte 5
Dhaka 5
Figino 5
Haiphong 5
Jeddah 5
Johannesburg 5
Memphis 5
Palermo 5
Riyadh 5
Shanghai 5
Barquisimeto 4
Bologna 4
Boston 4
Buenos Aires 4
Cairo 4
Caxias do Sul 4
City of London 4
Florence 4
Goiânia 4
Houston 4
Kathmandu 4
North Bergen 4
Poplar 4
Stockholm 4
Vienna 4
Amman 3
Atlanta 3
Belo Horizonte 3
Benevento 3
Bishkek 3
Biên Hòa 3
Brasília 3
Brussels 3
Curitiba 3
Da Nang 3
Florianópolis 3
Fortaleza 3
Greenville 3
Hortolândia 3
Manchester 3
Medellín 3
Montevideo 3
Montreal 3
Mumbai 3
Naples 3
Ninh Bình 3
Osasco 3
Pagani 3
Phoenix 3
Quito 3
Ribeirão Preto 3
Roubaix 3
San Severo 3
Totale 1.648
Nome #
Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study 226
An overview of statin-induced myopathy and perspectives for the future 168
Crithmum maritimum Extract Restores Lipid Homeostasis and Metabolic Profile of Liver Cancer Cells to a Normal Phenotype 121
A multicomponent personalized prevention program in the primary care setting: a randomized clinical trial in older people with noncommunicable chronic diseases (Primacare_P3 study) 108
Cellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis 104
Anti-inflammatory properties of an aldehydes-enriched fraction of grapefruit essential oil 86
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes 83
Alcoholic liver cirrhosis, more than a simple hepatic disease - A brief review of the risk factors associated with alcohol abuse 83
A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study 74
Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study 72
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors 67
Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 months prospective study 67
Preliminary results of CitraVes™ effects on low density lipoprotein cholesterol and waist circumference in healthy subjects after 12 weeks: A pilot open-label study 64
Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study 62
Dysfunctional mitochondrial bioenergetics sustains drug resistance in cancer cells 56
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect 55
Microenvironmental stress drives tumor cell maladaptation and malignancy through regulation of mitochondrial and nuclear cytochrome c oxidase subunits 54
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study 54
An evaluation of RVX-208 for the treatment of atherosclerosis 52
Drug evaluation: The combination of fenofibrate and simvastatin for the treatment of dyslipidemia: When and for whom? 52
Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients with Metabolic Syndrome 51
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? 48
Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect 48
Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review) 47
Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers 47
Anti-cytokine therapy for prevention of atherosclerosis 47
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children 43
Can the effects of gender, menopause and ageing on lipid levels be differentiated? 42
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study 42
Adipokines and lipoproteins: Modulation by antihyperglycemic and hypolipidemic agents 38
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia 37
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study 35
Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives 35
Should low high-density lipoprotein cholesterol (HDL-C) be treated? 33
Effects of chitosan on plasma lipids and lipoproteins: A 4-month prospective pilot study 32
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality 31
Management of Statin Intolerance in 2018: Still More Questions Than Answers 31
LDL and HDL subfractions, dysfunctional HDL: treatment options 30
Natural approaches in metabolic syndrome management 26
Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation 26
The Role of Nutraceuticals in Statin Intolerant Patients 26
Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan 25
Intensive LDL-cholesterol lowering therapy and neurocognitive function 25
Periodontitis, blood lipids and lipoproteins 24
Uric acid metabolism in pre-hypertension and the metabolic syndrome 24
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis 24
Exosomal Heat Shock Proteins as New Players in Tumour Cell-to-Cell Communication 22
The role of fibrate treatment in dyslipidemia: an overview 22
Resistin: An inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome 21
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms 21
Peroxisome proliferator-activated receptors and atherosclerosis 21
Nutraceuticals as new therapeutic strategies for health and wellbeing 21
Nutraceuticals as lipid-lowering treatment in pregnancy and their effects on the metabolic syndrome 20
The extra-glycemic effects of liraglutide: Focus on cardiometabolic markers 20
Oxidative stress and the role of antioxidative treatment in diabetes mellitus 20
Involvement of the ADAM 12 in thrombin-induced rat's VSMCs proliferation 20
Small, dense LDL: an update 20
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials 20
The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: Current knowledge and future perspective 20
Subfractions and subpopulations of HDL: An update 19
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pilot study 19
Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel 18
Psoriasis and acute coronary syndrome risk 18
Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease 18
Incretins, pregnancy, and gestational diabetes 18
Regulation of inducible Nitric Oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure 18
Novel anti-obesity drugs and plasma lipids 18
Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches 18
Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel 17
The effect of bergamot on dyslipidemia 17
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study 17
Serum low density lipoprotein subclasses in asthma 17
EXOSOMES: PROMISING NON-INVASIVE DIAGNOSTIC AND THERAPEUTIC TOOLS 17
Nutraceuticals as an important part of combination therapy in dyslipidaemia 16
ETC-1002: A future option for lipid disorders? 16
IMPROVE-IT: What have we learned? 16
Gestational diabetes and the metabolic syndrome: can obesity and small, dense low density lipoproteins be key mediators of this association? 16
The dissociation of the Hsp60/pro-Caspase-3 complex by bis(pyridyl)oxadiazole copper complex (CubipyOXA) leads to cell death in NCI-H292 cancer cells 16
Serum lipoproteins are not associated with the severity of asthma 16
Emerging approaches for the treatment of hypertriglyceridemia 15
Statin treatment in the elderly: how much do we know? 15
Statins and new-onset diabetes 15
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg) 15
PPAR agonists, atherogenic dyslipidemia and cardiovascular risk 14
Incretin-based therapies, glucometabolic health and endovascular inflammation 13
GLP-1 receptor agonists, carotid atherosclerosis and retinopathy 12
Totale 3.337
Categoria #
all - tutte 15.759
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.759


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202393 0 0 0 0 0 0 0 0 0 0 90 3
2023/2024114 0 0 1 80 0 3 0 2 7 3 5 13
2024/2025802 15 3 38 18 33 43 56 75 44 30 127 320
2025/20262.133 341 134 144 237 203 99 179 52 205 213 172 154
2026/2027195 195 0 0 0 0 0 0 0 0 0 0 0
Totale 3.337